WDFY3

Across TCGA pan-cancer cohorts, WDFY3 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated WDFY3 data layer compared with 27 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in uterine carcinosarcoma (UCS), where higher WDFY3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated WDFY3 expression acts as an unfavorable survival marker, although some lineages such as HNSC and UCEC show a favorable association.

UCS, LUAD, and HNSC are the cancer types where WDFY3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCS	OS	Median	All	0.007	0.689	<.001	24	view →
LUAD	OS	Median	III,IV	0.083	0.680	<.001	18	view →
HNSC	OS	Median	III,IV	0.937	0.612	.016	17	view →
UCEC	DFS	Median	All	0.855	0.607	.020	8	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
STAD	OS	Median	II,III,IV	0.807	0.391	.037	2	view →
SKCM	OS	Median	All	0.743	0.879	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

WDFY3–UCS (OS)

Open the UCS breakdown →